title: [Primary mediastinal germs cells tumors: a twenty years experience in a comprehensive cancer center].
abstract: The aim of this study is to report treatments results of patients with primary germ cell tumors (GCTs) of mediastinum.
  
  
  METHODS
  A retrospective review was done of 19 consecutive patients with mediastinal GCTs treated in "Institut de cancérologie de Lorraine" between 1990 and 2012.
  
  
  RESULTS
  A total of 19 patients were enrolled in this study. Three patients had pure seminoma and 16 patients had non-seminomatous germ cell tumors. All patients were treated with cisplatinum based chemotherapy at a dose of 33.48 mg/m(2)/week. At the end of chemotherapy, three patients (15.8%) had complete response and negative marker, seven of them (36.8%) had partial response and negative marker, five of them (26.32%) had partial response and positive marker, three of them (15.8%) had progressive disease (refractory disease) and one patient died because of the disease during treatment. The 1-year and 5-year overall survival rates were respectively 78 and 36% and the progression-free survival rate was 43%. When relapse occurred, this happened within a 13 month period.
  
  
  CONCLUSIONS
  Our study confirmed the good management of mediastinal GCTs in our institute with similar results compared to literature.
authors.affiliation: Hôpital Henri Mondor, Oncologie médicale, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Joly
authors.affiliation: Institut de cancérologie de Lorraine, 6, avenue de Bourgogne, 54500 Vandœuvre-lès-Nancy, France.
authors.forename: Mathilde
authors.initials: M
authors.lastname: Deblock
authors.affiliation: Institut de cancérologie de Lorraine, 6, avenue de Bourgogne, 54500 Vandœuvre-lès-Nancy, France.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Desandes
authors.affiliation: Institut de cancérologie de Lorraine, 6, avenue de Bourgogne, 54500 Vandœuvre-lès-Nancy, France.
authors.forename: Lionnel
authors.initials: L
authors.lastname: Geoffrois
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002173:Cancer Care Facilities; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D009364:Neoplasm Recurrence, Local / Q000401:mortality; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies; D018239:Seminoma / Q000188:drug therapy / Q000401:mortality; D013736:Testicular Neoplasms; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin; D007069:Ifosfamide
keywords: germ cell tumors; mediastinum; non-seminomatous germ cell tumors; seminoma